50.10
+0.09(+0.18%)
Currency In USD
| Previous Close | 50.01 |
| Open | 50.1 |
| Day High | 50.18 |
| Day Low | 49.5 |
| 52-Week High | 51.43 |
| 52-Week Low | 12.21 |
| Volume | 197,907 |
| Average Volume | 568,525 |
| Market Cap | 1.39B |
| PE | -17.77 |
| EPS | -2.82 |
| Moving Average 50 Days | 39.99 |
| Moving Average 200 Days | 26.71 |
| Change | 0.09 |
If you invested $1000 in AnaptysBio, Inc. (ANAB) since IPO date, it would be worth $2,947.06 as of December 29, 2025 at a share price of $50.1. Whereas If you bought $1000 worth of AnaptysBio, Inc. (ANAB) shares 5 years ago, it would be worth $2,320.52 as of December 29, 2025 at a share price of $50.1.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Anaptys Announces Participation in December Investor Conferences
GlobeNewswire Inc.
Nov 25, 2025 9:15 PM GMT
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer o
Anaptys Announces $100 Million Stock Repurchase Plan
GlobeNewswire Inc.
Nov 21, 2025 9:00 AM GMT
SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized an amended Sto
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
GlobeNewswire Inc.
Nov 21, 2025 8:50 AM GMT
SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced it has filed a Verified Complaint in Delaware Chancery Court, r